These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 9820230

  • 1. B-90063, a novel endothelin converting enzyme inhibitor isolated from a new marine bacterium, Blastobacter sp. SANK 71894.
    Takaishi S, Tuchiya N, Sato A, Negishi T, Takamatsu Y, Matsushita Y, Watanabe T, Iijima Y, Haruyama H, Kinoshita T, Tanaka M, Kodama K.
    J Antibiot (Tokyo); 1998 Sep; 51(9):805-15. PubMed ID: 9820230
    [Abstract] [Full Text] [Related]

  • 2. The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1.
    Raoch V, Martinez-Miguel P, Arribas-Gomez I, Rodriguez-Puyol M, Rodriguez-Puyol D, Lopez-Ongil S.
    Br J Pharmacol; 2007 Oct; 152(3):313-22. PubMed ID: 17643133
    [Abstract] [Full Text] [Related]

  • 3. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Ksander GM, Savage P, Trapani AJ, Balwierczak JL, Jeng AY.
    J Cardiovasc Pharmacol; 1998 Oct; 31 Suppl 1():S71-3. PubMed ID: 9595404
    [Abstract] [Full Text] [Related]

  • 4. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.
    Kukkola PJ, Savage P, Sakane Y, Berry JC, Bilci NA, Ghai RD, Jeng AY.
    J Cardiovasc Pharmacol; 1995 Oct; 26 Suppl 3():S65-8. PubMed ID: 8587470
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11.
    Trapani AJ, De Lombaert S, Kuzmich S, Jeng AY.
    J Cardiovasc Pharmacol; 1995 Oct; 26 Suppl 3():S69-71. PubMed ID: 8587471
    [Abstract] [Full Text] [Related]

  • 7. N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities.
    Inguimbert N, Poras H, Teffo F, Beslot F, Selkti M, Tomas A, Scalbert E, Bennejean C, Renard P, Fournié-Zaluski MC, Roques BP.
    Bioorg Med Chem Lett; 2002 Aug 05; 12(15):2001-5. PubMed ID: 12113828
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Attenuation of puromycin aminonucleoside-induced glomerular lesions in rats by CGS 26303, a dual neutral endopeptidase/endothelin-converting enzyme inhibitor.
    Feldman DL, Mogelesky TC, Chou M, Jeng AY.
    J Cardiovasc Pharmacol; 2000 Nov 05; 36(5 Suppl 1):S342-5. PubMed ID: 11078415
    [Abstract] [Full Text] [Related]

  • 10. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
    Trapani AJ, De Lombaert S, Beil ME, Bruseo CW, Savage P, Chou M, Jeng AY.
    Life Sci; 2000 Nov 05; 67(9):1025-33. PubMed ID: 10954036
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors.
    Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJ.
    Circulation; 1996 Nov 01; 94(9):2131-7. PubMed ID: 8901663
    [Abstract] [Full Text] [Related]

  • 13. Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitro.
    Maguire JJ, Kuc RE, Davenport AP.
    Br J Pharmacol; 2001 Nov 01; 134(6):1360-6. PubMed ID: 11704658
    [Abstract] [Full Text] [Related]

  • 14. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
    Wallace EM, Moliterni JA, Moskal MA, Neubert AD, Marcopulos N, Stamford LB, Trapani AJ, Savage P, Chou M, Jeng AY.
    J Med Chem; 1998 Apr 23; 41(9):1513-23. PubMed ID: 9554884
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhibition of neointima formation in an organ culture of human saphenous vein: a comparison of dual endothelin-converting enzyme/neutral endopeptidase and selective neutral endopeptidase inhibition.
    Porter KE, Dickinson T, London NJ.
    J Vasc Surg; 2001 Sep 23; 34(3):548-54. PubMed ID: 11533610
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Molecular pharmacology of endothelin converting enzymes.
    Turner AJ, Murphy LJ.
    Biochem Pharmacol; 1996 Jan 26; 51(2):91-102. PubMed ID: 8615890
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats.
    Trapani AJ, Beil ME, Bruseo CW, De Lombaert S, Jeng AY.
    J Cardiovasc Pharmacol; 2000 Nov 26; 36(5 Suppl 1):S40-3. PubMed ID: 11078331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.